TSC2-mutant uterine sarcomas with JAZF1-SUZ12fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition

MLA

Chiang, Sarah, et al. “TSC2-Mutant Uterine Sarcomas with JAZF1-SUZ12fusions Demonstrate Hybrid Features of Endometrial Stromal Sarcoma and PEComa and Are Responsive to MTOR Inhibition.” Modern Pathology, vol. 35, no. 1, Jan. 2022, pp. 117–27. EBSCOhost, https://doi.org/10.1038/s41379-021-00922-7.

APA

Chiang, S., Vasudevaraja, V., Serrano, J., Stewart, C. J. R., Oliva, E., Momeni-Boroujeni, A., Jungbluth, A. A., Da Cruz Paula, A., da Silva, E. M., Weigelt, B., Park, K. J., Soslow, R. A., Murali, R., Ellenson, L. H., Benayed, R., Ladanyi, M., Abu-Rustum, N. R., Dickson, M. A., Cohen, S., … Konner, J. A. (2022). TSC2-mutant uterine sarcomas with JAZF1-SUZ12fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 35(1), 117–127. https://doi.org/10.1038/s41379-021-00922-7

Chicago

Chiang, Sarah, Varshini Vasudevaraja, Jonathan Serrano, Colin J.R. Stewart, Esther Oliva, Amir Momeni-Boroujeni, Achim A. Jungbluth, et al. 2022. “TSC2-Mutant Uterine Sarcomas with JAZF1-SUZ12fusions Demonstrate Hybrid Features of Endometrial Stromal Sarcoma and PEComa and Are Responsive to MTOR Inhibition.” Modern Pathology 35 (1): 117–27. doi:10.1038/s41379-021-00922-7.